Collector
Giriş Yap
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential | Collector
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s. Latest Ratings for INCY Date Firm Action From To Feb 2022 SVB Leerink Downgrades Market Perform Underperform Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 RBC Capital Upgrades Sector Perform Outperform View More Analyst Ratings for INCY View the Latest Analyst Ratings Importance Rank: 1 read more

Go to News Site